The House Judiciary Committee has launched an investigation into whether the Biden administration pressured the Food and Drug Administration (FDA) to speed up its approvals of COVID-19 booster shots.
In three April 10 letters to current and former FDA officials, Rep. Thomas Massie (R-Ky.)—who chairs the House Judiciary Subcommittee on the Administrative State, Regulatory Reform, and Antitrust—requested all records and materials relating to the agency’s review, approval, and promotion of all COVID-19 vaccines and boosters in addition to those regarding the departures of Dr. Marion Gruber and Dr. Philip Krause from the FDA’s Office of Vaccines Research and Review (OVRR).
“The Committee on the Judiciary is investigating allegations that the Biden Administration interfered in the U.S. Food and Drug Administration’s (FDA) authorization and licensure of the COVID-19 vaccines,” Massie wrote in a letter addressed to Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research (CBER).
“According to reports, two top FDA vaccine officials, Dr. Marion Gruber and Dr. Philip Krause, resigned in the wake of President Biden’s premature and rushed announcement in August 2021 calling for adults to receive a COVID-19 booster shot, which put undue pressure on FDA health officials to quickly authorize the vaccinations,” he noted.
Prior to their exits, Gruber and Krause—the other two letter recipients—served as the director and deputy director of the OVRR. Upon Gruber’s exit, Marks took over as acting director.
“President Biden broke his promise when it came to COVID-19 vaccines, most notably when it came to boosters, urging boosters from the White House bully pulpit before the boosters received FDA authorization,” the congressman wrote.
In addition to records relating to the vaccines’ authorization and the doctors’ departures, Massie also requested a list of all current and former OVRR employees from Jan. 1, 2020, to present.
The Epoch Times has contacted the FDA for comment.
In that probe, the FDA was given until March 24 to provide documents and transcribed testimony from Gruber, Krause, Marks, and FDA Principal Deputy Commissioner Janet Woodcock.